Image from pexels.com
For years, debates have swirled on whether aluminum-containing childhood vaccines could be linked to chronic health conditions such as allergies, autoimmune diseases, and neurodevelopmental disorders. Fueled by social media and misinformation, these concerns have persisted despite reassurance from scientists that vaccines are safe.
A massive Danish study was published on July 15, 2025 in the Annals of Internal Medicine that delivers some of the strongest evidence yet: aluminum in vaccines is not associated with chronic diseases in children.
Aluminum in Vaccines
Aluminum is not just for soda cans. It has been used in vaccines for generations. Aluminum salts, such as aluminum hydroxide and aluminum phosphate, are used as adjuvants in vaccines. Adjuvants work by improving the body’s ability to mount an immune response, thereby increasing vaccine potency. This enhanced immune response means reduced frequency of vaccinations and lower doses of antigen to achieve protection. As an adjuvant, aluminum is thought to bind vaccine antigen with great affinity resulting in the recruitment of immune cells to the injection site. Aluminum salts are used in a variety of vaccines including human papillomavirus (HPV), diphtheria, tetanus, and pertussis (DTap), haemophilus influenza type B (HIB), pneumococcus conjugates (PCV), and others.
Aluminum salts were first used as vaccine adjuvants in the 1920s. Despite their long history of safe use, some people remain concerned about a possible link between aluminum and chronic conditions. Regular ingestion of aluminum through food and water is generally considered safe. However, aluminum can be toxic when introduced in large quantities. At toxic levels, aluminum can interfere with physiologic processes, have neurotoxic effects, and deposit in bone and brain tissues. Aluminum in vaccines is given in small quantities far below toxic thresholds.
Vaccine Misinformation
Misinformation surrounding vaccines continues to circulate despite scientific evidence of safety and efficacy. In an age of social media, “fake news”, and politicalization of healthcare, misinformation surrounding vaccines spreads quickly resulting in negative impacts on health care. Misinformation can induce fear, influence health decisions, and lead to the distrust of healthcare experts. This is especially true among parents who are trying to make the safest choices for their children. Refusal of vaccinations puts patients at an increased risk for acquiring illnesses and creates a risk to public health.
Previous studies have also fueled fears about the safety of aluminum in vaccines. A study published in 2011 by the Journal of Inorganic Biochemistry concluded that aluminum from vaccines was linked to autism spectrum disorder. The study described aluminum as a neurotoxin and immune stimulator that has the potential to induce neuroimmune disorders. The World Health Organization’s Global Advisory Committee on Vaccine Safety (GACVS) later concluded the study was seriously flawed. They noted inappropriate study design, utilization of incorrect assumptions, and the use of questionable data.
New Evidence from Denmark
Public concern regarding a possible link between aluminum-containing vaccines and chronic conditions have persisted through the years. Moreover, robust studies on the safety of aluminum-containing vaccines are lacking. Researchers at Statens Serum Institute in Denmark set out to determine if there was a link between aluminum exposure from childhood vaccines and a variety of neurodevelopmental disorders, autoimmune disorders, and atopic or allergic conditions. Published on July 15, 2025, “Aluminum-Absorbed Vaccines and Chronic Diseases in Childhood: A Nationwide Cohort Study” examined data from over 1.2 million children and found no evidence that aluminum exposure increases the risk of chronic conditions.
This cohort study was conducted in Denmark between 1997 and 2020 utilizing Danish healthcare registries. The participants included 1,224,176 children born between 1997 and 2018. The study assessed the impact of cumulative aluminum exposure from early childhood vaccinations on 50 health conditions. Participants were analyzed for health conditions starting at age 2. They were followed though age 5, death, loss to follow-up, or until December 2020 (completion of the study). The intervention was assessed as cumulative aluminum exposure in 1 mg increments to account for variations in vaccines given per child, introduction of new vaccines, and changing vaccination recommendations.
Some examples of the health conditions studied are listed below.
Results
The results of the study found no association between aluminum-containing childhood vaccines and an increased risk of chronic health conditions.
For combined outcomes groups, adjusted hazard ratios per 1 mg increase in aluminum exposure were as follows:
- Autoimmune disorders: HR =0.98 (95% CI, 0.94 to 1.02)
- Atopic or allergic disorders: HR = 0.99 (95% CI, 0.98 to 1.01)
- Neurodevelopmental disorders: HR = 0.93 (95% CI, 0.90 to 0.97)
For most outcomes, the upper limits of the 95% confidence intervals rule out relative risk increases greater than 10-30%. This suggests the risk of these outcomes is unlikely to be increased due to aluminum exposure.
Researchers ruled out even small risk increases for the majority of conditions studied. When conditions were analyzed individually, the upper limits of 95% confidence intervals ruled out relative increases higher than 10% for 19 conditions, 30% for 7 conditions, and 31-79% for 4 conditions. These 4 conditions had much lower incidence rates.
The results of the study are consistent and reassuring, there is no increased risk of chronic childhood disorders associated with higher aluminum exposure.
Strengths and Limitations
This was a robust study with a large patient population of over one million children and spanning more than two decades. Additionally, utilizing patients from the general population reflects real world conditions.
The study had some limitations. Since data was collected from national registry data, researchers did not review individual medical records which may contain bias or discrepancies. The study was conducted in Denmark whose healthcare system is different than those of other countries. The Danish Health Authority provides recommended childhood vaccinations free of charge to Danish residents. Childhood vaccination rates are high. In 2023, childhood vaccination rates were 94-97% among children through age two.
Conclusion
Despite scientific evidence supporting vaccine safety, myths continue to spread suggesting vaccines or vaccine ingredients are dangerous. This misinformation fuels vaccine hesitancy, lowers vaccination rates, and increases risks to public health.
In an age of misinformation and viral social media posts, studies like this are essential. This study confirms what science, and doctors have known for decades: aluminum adjuvants are not linked to chronic diseases. This study provides a much-needed, real-world confirmation that aluminum-containing vaccines are safe. Having robust, scientific data available can help ease fears around the safety of vaccines.
Terese H., APPE Student
Resources
- Niklas Worm Andersson, Ingrid Bech Svalgaard, Stine Skovbo Hoffmann, et al. Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood: A Nationwide Cohort Study. Ann Intern Med. [Epub 15 July 2025]. doi:10.7326/ANNALS-25-00997
- Djurisic S, Jakobsen JC, Petersen SB, Kenfelt M, Klingenberg SL, Gluud C. Aluminium adjuvants used in vaccines. Cochrane Database Systematic Review. 2018 Jul 2;2018(7):CD013086. doi: 10.1002/14651858.CD013086. PMCID: PMC6373706.
- Vaccine misinformation and social media. Burki, Talha. The Lancet Digital Health, Volume 1, Issue 6, e258 – e259
- Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? Journal of Inorganic Biochemistry. 2011 Nov;105(11):1489-99. doi: 10.1016/j.jinorgbio.2011.08.008. Epub 2011 Aug 23. PMID: 22099159
- World Health Organization. Adjuvants. Global Advisory Committee on Vaccine Safety, World Health Organization, www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/adjuvants. Accessed 8/26/25.